The stock of Strides Pharma Science, after facing resistance at ₹800 in early August, witnessed a sharp decline in price. The sell-off resulted in the stock marking a low of ₹562.5 towards the end of August, thereby losing nearly 30 per cent within a month. But thereafter, the stock entered a consolidation phase, and it was largely fluctuating within ₹580 and ₹625.
However, on Tuesday, the stock breached the support of ₹580, opening the door for the next leg of downswing. The price action since August i.e., a decline followed by consolidation and then a break down is a clear bearish sign and indicators like the RSI and the MACD also remain in their respective negative territory.
Hence, traders can consider selling the stock at current level and short again if it rallies to ₹570. Place initial stop-loss at ₹590 and revise it downwards it down to ₹560 if the stock falls below ₹535. If the stock falls below ₹535 without rallying to ₹570, place stop-loss at ₹560. Targets can be ₹500 and ₹475.
(Note: The recommendations are based on technical analysis. There is a risk of loss in trading.)
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.